PharmaEngine

Phone: +886 2 2515–8228

Fax: +886 2 2515–7558

E-mail: info@pharmaengine.com

Web: https://www.pharmaengine.com/

PharmaEngine focuses on the development of new drugs for the treatment of cancer diseases. There are 2 projects in the pipeline. ONIVYDE® (PEP02, MM-398, nal-IRI), a new formulation of an anti-cancer drug (irinotecan) for the patients with gemcitabine-treated metastatic pancreatic cancer, so far, ONIVYDE® has received marketing approval in more than 40 countries, including Taiwan, US, EU, Australia, Canada, South Korea, and Japan. PEP07, a checkpoint kinase 1 (Chk1) inhibitor, which targets the DNA Damage Response (DDR) network, is currently in the pre-clinical stage.

For detailed contact information visit location pages below.